Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 8, 2026

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

Refractory Hodgkin lymphoma.

Bastian von Tresckow1, Andreas Engert

  • 1Department I of Internal Medicine, University Hospital Cologne bGerman Hodgkin Study Group (GHSG), Cologne, Germany. bastian.von-tresckow@uk-koeln.de

Current Opinion in Oncology
|August 15, 2013
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024
Same author

Human immunodeficiency virus-associated Lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

HemaSphere·2024
Same author

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial.

Lancet (London, England)·2024
Same author

Time-dependent cost comparison and health economic impact analysis of second-line interventions for transplant-ineligible patients with relapsed or refractory diffuse large B cell lymphoma.

European journal of haematology·2024
Same author

Human leukocyte antigen (HLA) class I expression on Hodgkin-Reed-Sternberg cells is an EBV-independent major determinant of microenvironment composition in classic Hodgkin lymphoma.

HemaSphere·2024
Same author

Prognostic Implications of <sup>68</sup>Ga-FAPI-46 PET/CT-Derived Parameters on Overall Survival in Various Types of Solid Tumors.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2024

Advances in Hodgkin Lymphoma treatment, including intensified chemotherapy and brentuximab vedotin, are improving outcomes for patients with refractory disease. New therapies offer hope for increased cure rates in this challenging condition.

Area of Science:

  • Hematology
  • Oncology
  • Clinical Trials

Background:

  • Refractory Hodgkin Lymphoma presents a significant therapeutic challenge with poor prognosis despite treatment advances.
  • Refractoriness can occur at initial diagnosis or develop during treatment, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To review recent therapeutic advances in managing refractory Hodgkin Lymphoma.
  • To highlight novel treatment options and their impact on patient outcomes.

Main Methods:

  • Evaluation of intensified chemotherapy regimens, such as BEACOPP escalated.
  • Assessment of autologous and allogeneic stem cell transplantation strategies.
  • Review of emerging therapies, including antibody drug conjugates like brentuximab vedotin.

More Related Videos

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Related Experiment Videos

Last Updated: May 8, 2026

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Main Results:

  • Intensified BEACOPP escalated chemotherapy improved tumor control and reduced refractory disease rates in early and advanced Hodgkin Lymphoma.
  • Tandem autologous transplant shows promise in managing refractory disease.
  • Brentuximab vedotin offers a highly effective treatment option for patients relapsing after autologous transplant and as a bridge to allogeneic transplant.

Conclusions:

  • Recent therapeutic progress has enhanced the prognosis for Hodgkin Lymphoma patients by preventing or effectively treating refractory disease.
  • Emerging drugs like brentuximab vedotin are expected to further improve cure rates for Hodgkin Lymphoma.